Limits...
Correlation between bone metastasis and thrombocytosis in pulmonary adenocarcinoma patients.

Zhang W, Yu C, Huang B, Zhou FL, Huang HD, Li Q - Oncol Lett (2014)

Bottom Line: In descending order of frequency, metastases were documented at the following sites: Lymph nodes (218/308 patients; 70.8%), bone (138/308 patients; 44.8%), lung (93/308 patients; 30.2%), brain (67/308 patients; 21.8%), liver (46/308 patients; 4.9%), adrenal glands (11/308 patients; 3.6%) and kidneys (5/308 patients; 1.6%).Bone metastasis occurred significantly more frequently in patients exhibiting thrombocytosis (50/82 patients: 61.0%; P<0.05) compared with patients not exhibiting thrombocytosis (88/226 patients; 38.9%).Therefore, patients exhibiting pulmonary adenocarcinoma and thrombocytosis have a higher risk of bone metastasis compared with patients not exhibiting thrombocytosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China.

ABSTRACT

Thrombocytosis is commonly observed in patients exhibiting a variety of malignancies, including pulmonary, gastrointestinal and hepatic cancer. In the present study, the correlation between distant metastasis and thrombocytosis was retrospectively reviewed in 308 cases of histopathologically confirmed pulmonary adenocarcinoma. The patients were classified as having thrombocytosis or not, based on their platelet counts upon diagnosis; thrombocytosis was documented in 82/308 patients (26.6%). A log-rank test indicated a statistically significant difference in survival between patients exhibiting thrombocytosis compared with patients not exhibiting thrombocytosis (P<0.001). In addition, the occurrence of distant metastasis and the survival period were correlated with the presence of thrombocytosis upon diagnosis. In descending order of frequency, metastases were documented at the following sites: Lymph nodes (218/308 patients; 70.8%), bone (138/308 patients; 44.8%), lung (93/308 patients; 30.2%), brain (67/308 patients; 21.8%), liver (46/308 patients; 4.9%), adrenal glands (11/308 patients; 3.6%) and kidneys (5/308 patients; 1.6%). Bone metastasis occurred significantly more frequently in patients exhibiting thrombocytosis (50/82 patients: 61.0%; P<0.05) compared with patients not exhibiting thrombocytosis (88/226 patients; 38.9%). Furthermore, according to univariate analysis, thrombocytosis, weight loss, an Eastern Cooperative Oncology Group performance status score of ≥2 points, anemia, increased erythrocyte sedimentation rate, and increased alkaline phosphatase (AKP) and carcinoembryonic protein (CEA) levels were risk factors for bone metastasis. According to multivariate analysis, thrombocytosis, weight loss, and increased AKP and CEA levels were correlated with bone metastasis. Therefore, patients exhibiting pulmonary adenocarcinoma and thrombocytosis have a higher risk of bone metastasis compared with patients not exhibiting thrombocytosis.

No MeSH data available.


Related in: MedlinePlus

Survival was significantly poorer in patients exhibiting thrombocytosis compared with patients not exhibiting thrombocytosis (P<0.001). w, weeks; MST, mean survival time.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4301510&req=5

f2-ol-09-02-0762: Survival was significantly poorer in patients exhibiting thrombocytosis compared with patients not exhibiting thrombocytosis (P<0.001). w, weeks; MST, mean survival time.

Mentions: By final follow-up, 244/308 study patients had died and 64 study patients had survived. The one- and three-year survival rates were 76.0 and 31.5%, respectively. The 82 thrombocytosis patients had a mean survival time (MST) of 60.7 weeks (range, 3.6–235.9); however, the 226 non-thrombocytosis patients had an MST of 111.6 weeks (range, 16.6–299.0). Inter-group differences between one- and three-year survival rates (P<0.001; Table III) and within overall survival (log rank, χ2=43.095; P<0.001; Fig. 2) were statistically significant.


Correlation between bone metastasis and thrombocytosis in pulmonary adenocarcinoma patients.

Zhang W, Yu C, Huang B, Zhou FL, Huang HD, Li Q - Oncol Lett (2014)

Survival was significantly poorer in patients exhibiting thrombocytosis compared with patients not exhibiting thrombocytosis (P<0.001). w, weeks; MST, mean survival time.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4301510&req=5

f2-ol-09-02-0762: Survival was significantly poorer in patients exhibiting thrombocytosis compared with patients not exhibiting thrombocytosis (P<0.001). w, weeks; MST, mean survival time.
Mentions: By final follow-up, 244/308 study patients had died and 64 study patients had survived. The one- and three-year survival rates were 76.0 and 31.5%, respectively. The 82 thrombocytosis patients had a mean survival time (MST) of 60.7 weeks (range, 3.6–235.9); however, the 226 non-thrombocytosis patients had an MST of 111.6 weeks (range, 16.6–299.0). Inter-group differences between one- and three-year survival rates (P<0.001; Table III) and within overall survival (log rank, χ2=43.095; P<0.001; Fig. 2) were statistically significant.

Bottom Line: In descending order of frequency, metastases were documented at the following sites: Lymph nodes (218/308 patients; 70.8%), bone (138/308 patients; 44.8%), lung (93/308 patients; 30.2%), brain (67/308 patients; 21.8%), liver (46/308 patients; 4.9%), adrenal glands (11/308 patients; 3.6%) and kidneys (5/308 patients; 1.6%).Bone metastasis occurred significantly more frequently in patients exhibiting thrombocytosis (50/82 patients: 61.0%; P<0.05) compared with patients not exhibiting thrombocytosis (88/226 patients; 38.9%).Therefore, patients exhibiting pulmonary adenocarcinoma and thrombocytosis have a higher risk of bone metastasis compared with patients not exhibiting thrombocytosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China.

ABSTRACT

Thrombocytosis is commonly observed in patients exhibiting a variety of malignancies, including pulmonary, gastrointestinal and hepatic cancer. In the present study, the correlation between distant metastasis and thrombocytosis was retrospectively reviewed in 308 cases of histopathologically confirmed pulmonary adenocarcinoma. The patients were classified as having thrombocytosis or not, based on their platelet counts upon diagnosis; thrombocytosis was documented in 82/308 patients (26.6%). A log-rank test indicated a statistically significant difference in survival between patients exhibiting thrombocytosis compared with patients not exhibiting thrombocytosis (P<0.001). In addition, the occurrence of distant metastasis and the survival period were correlated with the presence of thrombocytosis upon diagnosis. In descending order of frequency, metastases were documented at the following sites: Lymph nodes (218/308 patients; 70.8%), bone (138/308 patients; 44.8%), lung (93/308 patients; 30.2%), brain (67/308 patients; 21.8%), liver (46/308 patients; 4.9%), adrenal glands (11/308 patients; 3.6%) and kidneys (5/308 patients; 1.6%). Bone metastasis occurred significantly more frequently in patients exhibiting thrombocytosis (50/82 patients: 61.0%; P<0.05) compared with patients not exhibiting thrombocytosis (88/226 patients; 38.9%). Furthermore, according to univariate analysis, thrombocytosis, weight loss, an Eastern Cooperative Oncology Group performance status score of ≥2 points, anemia, increased erythrocyte sedimentation rate, and increased alkaline phosphatase (AKP) and carcinoembryonic protein (CEA) levels were risk factors for bone metastasis. According to multivariate analysis, thrombocytosis, weight loss, and increased AKP and CEA levels were correlated with bone metastasis. Therefore, patients exhibiting pulmonary adenocarcinoma and thrombocytosis have a higher risk of bone metastasis compared with patients not exhibiting thrombocytosis.

No MeSH data available.


Related in: MedlinePlus